Latest / Two PhDs on a Pod / What the Most Measured Human Can Teach Us About Health
Transcript
- Guru Banavar: Hey guru. So today, we want to talk about measuring biology, okay? And when I talk to a random person in my circle on the street and so forth, maybe I can expect them to know a few things about themselves and their biology, like you're of course you'll know your height and your weight, maybe people know something about their H B A one C or you know something because they they've been taking a C GM or whatever, and maybe they'll know something about the cholesterol or whatever. That's true. yeah, most people don't know a lot about their biology and they don't measure a lot about their biology. Yeah, that's because ⁓ the ⁓ deeper biology is not necessarily easily accessible. But today, we have a guest who probably ⁓ knows more about their biology than anyone else in the world. And he probably knows so much that he probably knows his entire proteome as of like three o'clock yesterday afternoon. Man Okay. Proteome. So what is that? Right? Most people don't even know what a proteome is. I I know what proteins are. I know that there are a lot of proteins, but what is what is the proteome? And and protein is the basis for the word proteome, and ohm just means a collection of. So proteome is a collection of proteins that are found in our body. And proteome comes from human proteins as well as microbial proteins. And those are really the workhorses of our physiology. Those are the those are the actual molecules that perform The functions that keep us alive and keep us functional and keep us talking. And we have tens of thousands of those proteins. And you mentioned just a minute ago HBA1C. That is one of tens of thousands of proteins. And it's of course important for diabetes, but it's just one of tens of thousands. And so, yes, I can go get my HBA1C tested, but our guest on today's podcast will go and measure tens of thousands of proteins. like on a regular basis, which is So Momo, how do you keep how do you keep track of tens of thousands of anything? It's like how you know, what what does he make out of all of that data that he has? Is it is it like he somehow aggregates it into some higher level things that he can understand? Or is it, you know, in a traditional it seems to me like in traditional drug discovery or, you know, drug development, you look for certain very specific proteins that has been studied and then target it and inhibit it or amplify it or something like that. But what do you do when you have that much data about your proteo? Well, you know you know this better than anyone else, but we're going to discuss all the details with ⁓ our guests today. ⁓ but yeah, we're gonna be looking at patterns. We're gonna be discussing how patterns change from healthy state to disease state and how you can harness ⁓ those data sets in order to predict disease and potentially reverse or prevent disease. So that's pretty amazing. Yeah. I think ⁓ our our guest, Dr. Mike Snyder from Stanford, I cannot wait to talk to him and ⁓ look forward to bringing him on. Yeah, yeah. I think ⁓ he's probably the most measured person in the world, and we're gonna die deep dive deeper into all of those things. So I'm excited about today's episode. My name is Momo, I'm a biochemist. And my name is Guru, I'm an AI expert. We're two PhDs on a park. So, Mama, let me start with ⁓ what's on my radar and then you can go. Let's go. Yeah. So ⁓ listen, when I was growing up in India, we did not study the sort of the Western ⁓ epics. ⁓ nor did we study the Western ⁓ history, really. We studied Indian epics and we studied Indian history. Like, you know, we studied the Mahabharata, we studied the Ramayana, we studied you know, many other things about, you know, the Vedas and the Upanishads and all that. But we did not study ⁓ Homer. And and so it it was sort of like, you know, for me, I mean, now that I've lived in the Western world for a long time, for me there was a kind of a gap in my head about, you know, the basics of the culture of the Western world. So when the movie The Odyssey came out, which just came out a couple of weeks ago, I was super excited because I wanted to kind of catch up. I'm I'm a little bit of a you know history history buff whenever I can. I want to catch up. So I wanted to watch this in, you know, grand epic proportions and everything. So I went to this thing and ⁓ I mean, first of all, the movie is is totally ⁓ impactful on your on your brain and your mind and and everything. And the story is quite interesting with all the magic and with the with the scenes and you know his journey and all of that. ⁓ that stuff. However, I gotta say, it feels like, you know, one of the side stories of the Mahabharata. That's how it feels like to me. Because the Mahabharata is like a hundred times or something. I don't know how many times exactly, but it's a hu it's a very long story. You can ne literally you can never finish it. You know? And there are these tiny stories that happen like on the side and then you come back to the main story. Then you there's another tiny story and you come back. But it feels like the Odyssey is one of those side stories. I mean, I mean not to put it down anything but That's how I feel about it, okay, when I when I watch this story. Well, I would say given the ratio of the population of India versus Greece, I think a hundred times is perfectly fine. Yeah, yeah, it is. No, it's it's a great story. I love the movie. I love the story. but I gotta say I get a lot more from the Mahabharata than I I did from this this particular story. But anyway, so that was one thing. ⁓ the other thing that's super Interesting to me that's been on my radar in the last few weeks is the hormone estrogen, which I, you know, personally, of course, did not know much about. First of all, it's ⁓ it's one of the three or or so major hormones in reproductive health for for human beings, right? For estrogen is such an important part of female ⁓ reproductive health. It also plays a role, significant role, it turns out, in in in male. Health overall, especially with bone and and muscle and all of that. But it plays a an outsized role in the cycle of reproductive activity in females. Before, I mean, when when they when they ⁓ mature and they start their fertility cycle, there's there's all of these, you know, 30-day or 28-day cycle that happens with with estrogen that follows, you know, menstruation. And then when Menopause occurs, which is literally a day in the life of a woman when the estrogen cycle kind of, you know, slows down and almost halts. ⁓ and then from menopause onwards, it's like a flat line, so to speak, with not much activity going on, and also it lowers it quite a lot. There are significant impacts of on the physiology of women. So I've been learning about this stuff, and hopefully we'll do an episode on this topic because we are We've discovered a lot of really interesting molecular patterns in the gut microbiome that impacts your I mean, if you're a female with with these estrogen patterns, it impacts your health across many different systems. Bone, of course, muscle, heart health, your your your mood and your weight, you know, metabolic activity, all of these things get impacted by estrogen. So I found it like really fascinating to just understand for you know f for the first time, you know, the role of of a hormone like estrogen. And just just to finish that thought, I just want to also say, of course, for men, there is testosterone, which is a very important ⁓ reproductive hormone. There's a role it plays in in women's health as well. And ⁓ and then there's progesterone, right? So these are the three major hormones for reproductive health. And I'm Really enjoying learning all about it. And and ⁓ I agree that we should have an episode just dedicated to testosterone and estrogen. ⁓ because there's a lot of ⁓ there's a lot of myths out there, especially with ⁓ HRT that have recently been ⁓ you know debunked and also with testosterone. And ⁓ I think there's just a lot of conflicting information. And we now have quite a bit of data that we can also reveal. So that's gonna be exciting. And I also want to mention here as a little side note that People can read about it and we'll post it in the show notes if I remember. But basically, ⁓ a guy had IBD and chronic IBD that doctors couldn't do anything about. And basically they scheduled him for a resection, meaning they're gonna cut his colon off. And that really has a severe impact on the quality of life for the rest of your life. And as i in a moment of desperation, he read about fecal microbiotransplants and he basically asked his mom if She will donate her poop to him for an FMT. And she did. And ⁓ it turns out that she was in menopause and she had hot flashes. And after the fecal transplants, he developed hot flashes. And that made the news because it actually cured him of IBD, but it brought on hot flashes. And now they can actually discuss hot flashes together, which is kind of like funny story. But it tells you how the microbiome. Plays an important role in estrogen metabolism and its effects on the physiology. Super interesting story. Super interesting story. So Momo, what's on your radar? Woo, too many things, but let's let's ⁓ let's go quickly. ⁓ if you can go, if you can show the slides, please, Guru. ⁓ I'll bring it up. Keep talking. I I live to eat, so I'm all I'm always, always, always excited about food. And this Mediterranean spread that Guru is gonna show you, this is like one of my favorite, favorite meals. I just drool over that. And we make this semi-regularly, you know, there's a lot of competition from so many different cuisines, but this Mediterranean spread I think is fairly easy to make at home. And it's super tasty and it consists of three basically dishes. It's Baba Ganoush, it's hummus, and it's taboo salad. And so i if you can also on top of that make whole wheat pita bread at home, which is really not that difficult. You start in the morning and you you just the bread, you know, the dough rises during the course of the day. And you cook the the pita bread in the evening, not that complicated. So on like on a weekend, you can do that. ⁓ this is just phenomenally healthy for a lot of people, and it's super, super, super tasty. It's like really a s it it creates a strong emotional connection with food. So highly recommend that. This ⁓ these pictures, these p pictures as usual are mouth watering. And ⁓ I wanna I wanna ask you, is there any stuffing? inside this pita or this is just a plain pita it just it's just a plain pita. Those are just plain pita, right. And then ⁓ yeah, there is no stuffing. You just basically use pita to eat the food because ⁓ you know Baba Ganoush and hummus are basically finger foods. You cut a piece of pita bread and you you dig in. Wow. So really enjoy that and and hope that some audience members will go and find recipes which are plentiful. There are infinite number of varieties of these recipes depending on whether We're talking about Lebanon or Israel or ⁓ or ⁓ Jordan or Syria. All of those have slight slightly different variations, but it's kind of the same thing for us. So yeah, go out on a weekend and go get the ingredients and go make it from scratch, and you will likely l love it. Okay, next one that I'm excited about is sprouted wheat. We actually had a specific ⁓ specific request to talk a little bit more about how to make it. So I'll just outline how to make it. ⁓ you're you're basically ⁓ sprouting wheat, which is a completely natural process. So there's nothing really funky you need to do, but it's here's how it goes. It takes exactly 48 hours. You go buy wheat groats or just whole grain at your local store like from a bin. It's typically like $1.50 or $2 per pound. ⁓ you're gonna basically wash the wheat and spread it into a baking pan like I did right there on the left side, upper left side. ⁓ so you're gonna Wash it and then you're gonna soak it. So you're gonna submerge that wheat overnight. So you're gonna start the process one evening and 48 hours later it'll be ready. So that evening you're gonna wash the the wheat groats and soak them under water overnight. Then every morning and every evening for the next day and a half, ⁓ you're gonna drain the water. So in the morning, you're gonna drain that water and just leave the groats wet. Basically, you're gonna just drain majority of the water, leave the groats wet. I typically cover them with something depending on the humidity in your area. If you're in New Mexico, you're gonna need to cover them pretty well. If you're in, you know, the Pacific Northwest, you can cover them, but kind of leave it open. So the groats are going to be sprouting the next day, ⁓ and then you're gonna again rinse them in the evening and just leave them wet overnight. The next morning, you're gonna rinse them, leave them wet during the day, and 48 hours later you have sprouted wheat. Now, sprouted wheat, if you read about it, it you know, some influencers will claim magical nutritional benefits. There are mechanistic and molecular studies that show that some nutrients are more bioavailable from sprouted wheat and that it does have lower glycemic index, but really clinical trials haven't really shown any convincing sort of strong preference. So it's not like something that that is convincingly better than whole wheat by itself. ⁓ but it's fun to make and you can make dishes that are really fun. For example, the one I show in the in in the bottom ⁓ bottom part is what I grew up with. And it's basically just sprouted wheat and then a a thin layer of sugar that's mixed with with the wheat, and then a very thick layer of ground walnuts. That's it. And so adjust the ratios. And it's one of my favorite desserts that I absolutely love and it's also healthy. You know, walnuts are just packed with nutrients. Wheat is packed with nutrients. It's like taking multivitamin and omega-3 supplements and a whole bunch of other things. It's crazy. So I will write these steps actually in the show notes so that you don't have to worry about understanding what I just said because I'm too excited to be potentially ⁓ very sophisticated here. All right. One more thing I want to mention is I just want to highlight how important it is that people understand that the purpose of Viome, the company that Guru and I co run with Naveen is To translate scientific discoveries and into real life and and actually give them to people. And this is like our focus every single day, like literally every single day, including the weekends and holidays and so on. And so here's another major, major breakthrough in that over the last six months, we we worked in R D mode to convert a to to develop a new product. And we're this is our CLIA laboratory fully set up and now we're going through. We covered this in one of our previous episodes. You went through the the instruments and everything left to right. Exactly. Exactly. So we we did provide a little more detail. But the highlight of today is that we're now going through clinical validations and that this October, this is actually going to be released as a commercial product, which will be hugely advantageous. It's a food allergy and sensitivity test, but the cost is going to be remarkably. reduced over the competing tests. And that's really what we are about at VIOM is really not just bringing the most modern technology and putting it into people's hands, but making it affordable to as many demographics as we can. And this is another major effort. And we're going to talk about another effort that we're currently pursuing when it comes becomes more mature. But I just want that to highlight that Gudo and I work seven days a week to to bring technology to people's hands and and enable them to live a better life. So I'm really excited about that. Yes, so am I. I am looking forward to doing this test and also for everyone else to be able to access this test at that price point that you're talking about, which is very, very low. And and you know, Momo, I'll I'll I'll just ⁓ emphasize the same point is that if you don't translate the science, what is the point of the science, right? Yes, knowledge is is interesting and knowledge is good, sharing the knowledge, but if you cannot use it for something that makes people's lives better. What's the point? That's what we believe in biome and we translate all of the science. In fact, we do the science that we know we will translate. Otherwise we don't even do that science. Yep. Exactly. Lots of publications and everything. Time to ⁓ talk about all of this measurement of biology and everything else with ⁓ Dr. Mike Snyder. Very, very exciting to bring him on. So let's go get him in. Let's go. All right, so today's guest is Dr. Michael Snyder, a Stanford professor and pioneer in using genomics and multi-omics in general for personalized health. His work explores how molecular data and wearables can detect changes in health before symptoms appear. And we're going to spend a lot of time discussing that. Mike, welcome to two PhDs and a pod. Okay, great to be here. awesome. And you also found a Several startups. So we may have time to touch upon that as well. So Mike, we would like to start with you giving an overview of what you think are sort of the highlights of the last ten years of your career where you've used these multi-omic tools to track people over time or longitudinally to try to figure out what's wrong what's wrong with their physiology before actual symptoms onset. Yeah. Well, one is just the technology itself, the fact that we can now profile people incredibly deeply. You know, with the genome, the microbiome, all kinds of measurements, and the wearables, as I'm sure we'll get into. ⁓ so that you can get a much, much clearer picture of people's health. I would say that's one of the biggest things. I think some of the other highlights in our work are things like showing you can use wearables for detecting disease. ⁓ we're now subtyping diabetes. It's not simply type one, type two. ⁓ we think there are many subtypes of what people would call site. ⁓ type two, but it's actually before they get the type two. So we can actually ⁓ and that subtyping we think is important for their food responses, the drugs they take, things like that. So I think the ⁓ you know, in the Uber picture of things, we can see things, ⁓ we can, you know, profile health at a much different level than we're used to do. And then I think that's very, very powerful for treating people and it really is getting us closer to the goal of precision health, precision medicine. Yeah, Mike, ⁓ ⁓ let me let me actually ⁓ build on that. So I think the idea of individual variability ⁓ in your molecular profile and your biology overall is a very big theme on this particular podcast. We've had many episodes where we talk about that and our audience actually understood, hopefully, you if they've watched our previous episodes, they actually h heard us say that over and over again. We talk about glycemic response being individual, we talk about inflammation and all the other biochemical pathways being individual and so forth. But I want to ask you, you launched the field of personalized medicine in some way, right? And and you know the individual variability has been a part of your career and your work throughout. And you even predicted your own type 2 diabetes and stuff like that. So let me ask you, did knowing your molecular prediction change the outcome of what ended up happening in your own life, or did it kind of just give you a a head start on the behavioral interventions that you wanted to do? And You ended up in a different place than you would have if you did not know that. ⁓ yeah, totally changed the way things happen. One is as you just said, ⁓ we predicted my diabetes, which because I was kind of aware of it from my genome, we caught it when it first struck. ⁓ because of my case, which has happened now in other cases, I became diabetic after viral infection. It was first demonstrated ⁓ for that for type two diabetes. Been suspected for type one before that. and now that's actually very common for COVID. So I I basically caught it quickly, got it corrected initially by lifestyle, ⁓ and then to to come back. ⁓ and I'm I'm still struggling to get it as as optimal as possible. But anyway, I I think this whole ⁓ the the genome predicted it and and then this whole f tracking has helped me try to better manage it. And I I What what type of lifestyle interventions did you make? And and if if if ⁓ you use pharmacology, I would like to know that as well, please. Well, yeah, that's an interesting story there. So initially I got it under control just by lifestyle, just by running, cutting out carbs. I cut out all ultra processed food, cakes, muffins, all that stuff. And that got my diabetes under control. It then came back after I'd ⁓ stopped running and got another viral infection. And I got it partially under control, but never really got all the way to normal and gradually it kept getting worse and worse. I did try. Well, first I I Lifted weights, gained muscle mass, and ⁓ that worked in the sense I gained ten pounds of muscle mass, had a great trainer. ⁓ but it actually failed to control my glucose. And it turns out we think that's because a particular kind of diabetes ⁓ diabetic I am. I'm a beta cell defect, meaning insulin doesn't get out of my pancreas. and so ⁓ basically ⁓ w once it kept creeping up higher and higher, I shifted To try metformin that failed miserably. Actually, I turned out I'm metformin non responder. So then I went on to basically ⁓ one ⁓ figure out I was a beta cell defect. I didn't know before that. Then I figured it out, and then I went on to ⁓ try a drug called Rapignolide, which actually promotes insulin release from the pancreas, and that worked pretty well. ⁓ now these days, to be honest, I'm on the GLPs like a lot of other people. ⁓ and that also works well. But I'm also on the they're called SGLT two inhibitors for Segal is the one I take. And they also work. So those two I've switched to for a couple of reasons. One is they they do seem to work better. but I'll tell you the GLPs as great as they are, they actually do ⁓ I'm bit textbook. I I do have a bit of stomach nausea. ⁓ it's minor, it's you know, but it's there. and the other unwanted side effect is actually they do cause muscle mass loss. So all that muscle I gained from weightlifting, I would say it all disappeared, but quite a bit went away. ⁓ and then I really got very thin. In fact, I'm way thinner from when I started ⁓ to the point where a lot of people have looked at me and said, Well, ⁓ are you okay? Yeah. You know, what's going on there? You look pretty thin. And the answer is I'm actually quite healthy, except I'm on these GLPs, which have r you know, I'm the cold they've evaporated all my fat. I'm the coldest guy in the room. This kind of thing. So so I I'm I'm working on trying to gain some back. I should do ⁓ and I take one I I basically take the lowest dose one third the time and that is helping me balance my weight a little bit better. My glucose is that though a touch higher than I'd like. So again I'm always So the the ⁓ the amount of muscle mass, of course, is important for diabetics because you know the more muscle mass you have, the more surface area you have to be able to absorb ⁓ absorb the ⁓ you know, sugar, the insulin, all of these things, right? Yeah, well it's lean muscle mass in general, probably also helps you consume glucose better. ⁓ you know, muscle is very, very important for glucose consumption. So yeah. So I I guess it's that same concept you were saying. Okay, I'd like to get back to all the data because I've seen the data from Michael's presentations and it's fascinating how much data you've generated. I mean, you generate like a hundred or a thousand times more data than like a typical person who's like in the longevity space. And I I'd like to just for you to mention what data you're generating, first of all. And second of all, how can other people or when are normal people going to have access? Of course, now today, if I want to measure my APO B. It's very simple, right? Very easy to do that. There are many outlets, but the type of data you're measuring ⁓ are not really easily accessible to everyone, correct? Yeah, that's right. ⁓ so we measure my genome, ⁓ so my collection of DNA. We measure my transcriptome, so all the RNA that gets generated from the genome. This is a lot of blood, I should say. the proteome, the metabolum, the lipidum. In my case, we've also measured my auto antibody profiles, what antibodies I have that might be reactive with with other with pro human proteins. Can we can we just double click on that please? So your your genome, where where did you where where can people sequence their genome? Because most most of the genome services just provide SNPs or exomes, right? Yeah. Well, these days you can get whole genome. There's few companies, I'm not conflicted on these. Myome is one. I think Sophia Genetics is another. There's few out there. Okay. Five hundred dollars, they will sequence the whole genome. And they'll actually give you a limited interpretation. They usually look for ⁓ the they're these Mendelian genes as they're called, BRAC mutations, single gene mutations that that can put people high risk. So BRAC is the prototype. Apo E four, I'm sure, right? And Apo E ApoE three. Yeah, well a lot of them don't give the O Apo E because that's it it's questionable in terms of actionability. You can ask for it. ⁓ but it because it puts you at high risk for Alzheimer's. And it's not it's controversial whether you can do a whole lot for that. I personally think you can buy lifestyle a little bit, keep yourself ⁓ mentally engaged and such. But they they you d some of them will tell you the Apo E status. It depends on the company. Like Boston Hart will give you this. Okay. ⁓ but ⁓ many of them don't give you the Apo E status. Some do, some don't. ⁓ Anyway, ⁓ but things like ⁓ you know high risk for cholesterol, the a lot of cancer mutations. SHDB, for example, is one that you can get from the genome sequencing, single gene mutations. And it depends on the company, ⁓ but they give anywhere from about eighty or so genes up to maybe a hundred and twenty, depending on again on the company. ⁓ but it's not it's not a fully comprehensive analysis, but it it's It's probably the most actionable set ⁓ that are out there. So BRCA, for example, you'll get screened more if you have a BRCA mutation. ⁓ and then they do do polygenic risk scores. Some of them do, some of them don't. Yeah. That's a bit controversial in the genetic field, as you probably know. Yeah. Pologenic risk scores, they work well if you're at the extreme end of the g distribution. They don't work so well if you're sort of in the middle. Right. ⁓ so if you're in top two. Four percent than they'll work. But f so some people say it's a good idea to present them back. Some people say no. anyway. ⁓ Okay, let's let's move on to trans trans transcriptomics because that's super exciting because as you know, we're the only direct-to-consumer company that prov that actually measures metatranscriptome and not just the transcriptome ⁓ in terms of like human protein coding transcripts, which is what's typically done, but we do a metatranscriptomic analysis, meaning we also measure the non-coding RNAs. So how would you say we we could convert our metatranscriptomic analysis of blood into something that you would consider to be more useful beyond what we already provide? Momo, can I just add also that I did not hear Mike say microbiome yet, right? We're going to get to that we're going to get to that. We'll put everything together in the in the metatranscriptomic question. Right. Yeah, we can put it all together. I actually think the the microbiome we all know is super, super important. ⁓ it's been hard to ⁓ to get good and actionable, although that's now emerging thanks to companies like yours and a few others that are coming out there, where it is ⁓ now we are getting information from the microbiome we know how to act on. That was hard to get before, as you know, a number of companies entered this space and were not successful. ⁓ because they they you have to Turn it into, again, actionable information. And so I think your angle, the metatranscriptome, I think is quite unique. I think there is value to all that. I think on the on the transcriptome from the the host, like we measured out of the immune cells, peripheral blood monocyte cells, that actually has been harder to act on. Believe it or not, the proteome and the metabolome has been a little better when you're talking about the host. Now, the metatranscript or the transcriptome where you're looking for viruses or maybe other things. There are certain specific markers that are that are valuable. ⁓ but but people are now finding the we think that the ⁓ the proteome and and the metabolome are are better when you look at the host. Now that's a different scenario from the microbiome per se, where I think ⁓ not only what's going on in the microbiome, but how the genes are acting is a big deal. So ⁓ anyway that that's Mm my sense of this, I do think it's important to collect information that becomes actionable. So ⁓ and and that's where it's been hard for a lot of ⁓ groups to figure out the business model in this space. ⁓ and a good example was Arivale, which was collecting a lot of data for data sake. They built these data clouds, but no physician knew what to do with do with it. And so I think the key isn't build, yes, it's okay to build a data cloud. But it's got to be a data cloud that people can use, take action on. And that's what you guys are doing. I think as the field has moved along, people have come to realization that the information you get at the end has to be valuable. And I think again, we're finding that in the area of of proteins, metabolites. ⁓ you can see that there that information people can go on and and use. ⁓ these days use AI and such a pool together your information, the information from the literature, and the information you get from these tests make very predictive models that is actionable. Yeah. ⁓ my comment on that, Mike, is that for when it comes to proteomics, I think that there there are more data published that tie specific proteins to specific diseases. ⁓ and those are based on panels. They're not like metaproteomic analyses. They're literally panels, which is fine. That's great. And the same I think with metabolomics, you know, omega threes and omega sixes and lipidomics, things like that. So I think that ⁓ we're gonna we're gonna basically bring up this metatranscriptomic analysis association with diseases, which we already have, and and bring those and so I think I think that's a really good discussion, Guru, to ⁓ to really more robustly ⁓ exploit our ⁓ blood transcriptome data set from the human side. Yeah, well we can dig in on that because ⁓ I probably have a I do think there is value to those data sets. You're right. Traditionally they have been targeted panels, but now from a proteomics ⁓ profile, you and and metabolomics, you can see how people are aging, for example. You can get their age type, ⁓ which we think is very, very valuable if you are seeing and and the data are there in the scientific literature, but but you're right, they have not been traditionally measured. The transcriptome is much richer and that's why people focus on it. ⁓ I would argue the the meta proteom has almost not been studied on the meta metabolism. So, it's very unknown space. And it's a very complex space, right? So that so the the the way we the way we kind of ⁓ manage the complexity, Mike, is to look at the domain understood pathways that are coming from the meta transcriptomics, right? A classic example is ⁓ short chain fatty acid, right? We know a lot about short chain fatty acids in the in the gut and and and you know how it impacts physiology and so forth. So if you're able to see the activity of the tra the transcriptome, metatranscriptome with respect to short chain fatty acids, and then you're able to make ⁓ actionable suggestions, recommendations based on that activity, we think that is a that is a more sort of ⁓ an a concrete way of moving forward with the kind of data we have and the analysis we can do today. Yeah, 100% agree. At the right price point. At the right price point. Yeah, 100% agree. And you're hitting on two important concepts, in my opinion. One is this pathway level analysis. That's how you get understanding. Tritene fatty acids. Super important. ⁓ the other is ⁓ you're in the gut, you know, you're looking at the microbiome ⁓ and the meta transcriptome. So that is its own beast and it's a very, very important window in the health. Very understudied in my opinion. Very and and I think that's where you guys are pushing the boundaries. I think that's super, super important. ⁓ and you're able to take that information, use it again in an actionable form. ⁓ we don't yet know if the metaproteome would give the same information on the meta ⁓ the meta metabolome, if you will, would do the same. That's a lot trickier though, especially the metabolome when you're getting it out of the gut. So I think there are technical issues there, in the metabolum. But the proteum may have value too. I don't know. ⁓ just hasn't been explored the way you guys are diving in. And and what going on is very logical. You people started with the genome, right? The meta g genome, and then they saw what bacteria there and that gave some information. That has some value. You've taken it to the next level with the meta transcriptome, which Now he says what genes are there, which ones are active, and what pathways are going on. And I think that's that's super, super important. So I think you've taken that level. Whether the meta proteome adds on to that is I would say is an unanswered question. Right. Okay, Guru. ⁓ yeah, I have a I guess I wanted to I w I'm yes, ⁓ let me take the next question. So the the pathways can be associated very strongly with specific diseases. Like for example, inflammatory bowel disease, right? We have noticed that there are there are about eight or nine pathways that are highly involved in inflammatory bowel disease. And we now have a large enough data set for of inflammatory bowel disease people and people with no inflammatory bowel disease to be able to say that these specific pathways are active in the IBD or let's say Crohn's, for example. There's a pretty big difference between Crohn's versus colitis, right? So we can say in Crohn's, there's this type of pathways that are active and so forth. So in your Analysis of all of the ⁓ omics you have you have studied. I was wondering how you ignore sort of the transient noise and kind of specialize or isolate the relevant signals for specific diseases. You know, I I know you guys have done a lot of work in this area. I just want to get your sense of how you do that as a as a general principle. Yeah, well we're keen on individualized profiling, as you know. So we track individuals over time. And then you really have a sense of what their personal baseline is like. And that's very, very important. And it's all different. Your baseline, your heart rate, your blood oxygen, your skin temperature, they're all different from mine. ⁓ and from Momo's. So we're all different. ⁓ and so that's step one. And then in our case We're trying to catch disease early. So we sh see, we look for shifts from those baselines. And that has turned out to be very, very powerful. When I caught my Lyme disease, it's because my blood oxygen went down and my heart rate went up. All in advanced symptoms. Yeah. So you can see these things again for early disease detection. You've got to know your healthy baseline. Then you look for the shift up. ⁓ And I think again, there there are other cases that, but it it will only work if you know your healthy baseline, ⁓ because we're all different. Now, on the issue about ⁓ say disease versus healthy signals, that's valuable too. I mean, I think we want to be able to distinguish that. They're clearly markers. They tend to be a little bit later if you're only doing that, meaning ⁓ if because then use population average measurements, right? You look for things like CRP or markers, IBD, you're looking for I don't know what you you guys know better than me, f inflammatory markers, ⁓ I would assume. ⁓ and so I I think again that's valuable too, but I I think having good signatures and what I don't know, I'd love to hear more from you is how are you able to use that information for treatment subtyped? Can you subtype IBD? And therefore treat accordingly or not. I don't know if that's where you're going with your work. We do that for diabetes. We can actually now subtype diabetes based actually of all things on the shape of a glucose curve. We'll know your subtype and basically subtype determines what foods you should eat and what drugs you should take. And Mike, in our case, just to just to kind of put that on ⁓ on the on the table here. If you take IBS, right, there's so many subtypes of IBS, right? There's a constipation subtype, there's a diarrhea subtype, there's a mix subtype, and so on, right? We are able to isolate the specific pathways, like for example, sulfide production pathways or methane production pathways or serotonin pathways, and so on. We're able to isolate it, and we do have doctors, gastroenterologists who are looking at the pathway ⁓ activities to determine what kinds of treatments or that's perfect. That's exactly what we're doing. So based on their subtypes, then you can recommend specific treatments. Exactly. I think that's huge. And I again another area that I do know something about is MECFS, chronic fatigue syndrome, where same thing, it's a very heterogeneous disease. And so you want to really break it down and then based on people's essentially some the their tests you decide how to treat them. ⁓ so one of my companies rhythm does that. ⁓ so very, very I I'm totally keen on the subtyping. And so that comes back to your earlier ⁓ question, Guru, which is ⁓ to what you know extent can you tell disease signal from normal? Again, I think you can use some markers for that. I would love to be able to tell just on the person disease signal from normal. And IBS is a good example. IBD too, they have periods where they're perfectly normal, right? And then they shift away from that. But I would I l like where this conversation went to be able to subtype people based on these big data profiles and then treat them accordingly because most of these complex diseases, they're not just one thing. They're multiple things. And knowing that is very, very critical for the you know, the course of action. Yeah. Momo, back to you. I have tons of questions, but this the ⁓ E C C F S is such a big mystery and it it basically ⁓ completely grades the quality of life of the people who suffer from it. Can we just spend a couple of minutes on that? So ⁓ what what have you what have you seen in that disease and what can people what can what what should people know who's who are suffering from that disease in in terms of what tests are available that may have not been available you know in the last few years or what's coming up soon? What do you what do you think about I'm gonna say that I'm not a physician so you should go see your doctor for these sorts things. ⁓ Basically, ⁓ E C F S it's a real mystery. It's it's very heterogeneous. The one common thing they have is the fatigue, which ⁓ manifests itself after people overexert. and ⁓ but it's very, very different from one person to the next. Some people have heart issues associated with it. Some people it's fairly mild other people are bedridden. They literally can't get out of bed. Their their case is so extreme and then there's everything in between. Some people have ⁓ you know, gastrointestinal problems. It's all over the map. And so I would recommend in this case, I I probably won't venture far beyond where I'm at now, but I really think you do need to see specialists for this because they really can ⁓ the ones who know what they're doing will order the right tests. They they do look at your cytokines, they look at a variety of different markers, ⁓ and then based on those, they'll they'll They'll actually start some treatments, but they monitor those pretty carefully too to see which ones are working, how the markers shift. And that's another important part of the whole measurement space, not only just for the diagnostics, but also for monitoring treatments. And I I think this is super important. A good example is in the mental health space, you know, where we don't have, I know this is getting far ranging this conversation, but we don't have good markers for mental health. And so we don't It's very hard to see how people are responding to treatments. ⁓ you have to wait like three months, six months to see if anything's working. A fraction of them respond, most of them don't to most of these treatments. It's a real mess. So I do think that yeah, you know, I am a measurement guy. We're keen on making lots and lots of deep measurements on people to better figure out. And I I think that's an area that's really lacking in the mental health space. And I would argue to some extent, ⁓ E C F S there are more markers. And probably they would benefit by more Omics profiles. Yeah, and and and and in terms of measurement, Mike, ⁓ I know you're you're very big on wearables, which ⁓ I I I've I've heard a number of things ⁓ you've talked about ⁓ using we wearables for. ⁓ I wonder at a at a sort of ⁓ strategy level, do you sort of see that wearables are deep enough And high fidelity enough to be able to get to the broad range of chronic diseases. Or is it, you know, I I know it's infectious disease, it's it's it's relatively easy. I've actually had my aura ring ⁓ warn me one morning that I should not go running that day. I ignored it and went running and later that ⁓ you know and and then I collapsed somewhere and then I came back home. I came back home twelve kilometers later. I came back home and I I had COVID that that night. ⁓ and my my aura ring did that. So I believe that. wearables can give us information about these dramatic changes in your physiology, especially with respect to infectious diseases which happen quite ⁓ suddenly and and and intensely, right? But chronic disease is a very different beast, right? It's very slow. It's a very long range stuff. And you don't, you know, if even if you get so much data every day, I'm not sure how much noise versus signal there is in wearable data for long term are tracking of chronic dude. So what's what's your view on that? Couple of comments there. So first of all, I am a big fan of wearables. I have, you know, six of these four watches, two rings. You know, I I left my hearing aids upstairs. They're also sensors and I have several others. So ⁓ but and you know, here's my continuous glue coach. ⁓ there you go. All right. So anyway, ⁓ I am a big fan. ⁓ and yeah, not to toot my own horn, but we are the first to show right you can detect infectious disease from a simple smartwatch. but ⁓ anyway I think they go way beyond that. I think they will detect, but you you again I'll break down a little bit of what you brought up. ⁓ I think they can detect many diseases. We showed that with machine learning and AI now you would use deep learning. We can predict things like red blood cell count, hemocrit, which is sort of a blood marker, ⁓ Even fasting glucose and hemoglobin A1C you can predict from a smartwatch. They're not clinical grade measurements, but they're plenty good to see a shift from baseline. So I and I think you'll be able to see a a lot more. That was done with the 2016 watch. So I know we can do even better. ⁓ I think and the others have shown you pick up AFib now. We had a case that we're trying to get published where it's a little bit of a sad story where there's an individual, super fit guy in the lab, 76 years old. You look at him, you think this guy's great, and he was great. He's he's doing well. And then suddenly he dies one day after running on a Peloton right after. So his wife shares his his aura ring data, his smartwatch data, and we look at it, and sure enough, there's a step function change that occurred four and a half months prior to his catastrophic event. And it turns out that his heart rate went up, his heart rate variability dropped. His ⁓ gait shifted, his sleep shifted, his step count shifted, all these things were there. And that hits the point that you're raising. The information was there, but it was not relayed back. There was no system for taking this, relaying back to them to say, hey, something's off here. Maybe you should go get that checked out, or maybe you shouldn't run. He ran one of his hardest times ever on the Peloton. So we need a mechanism for taking this information, feeding it back to people. And I predict it's going to be valuable for IBS and IBD too, this kind of information too, where maybe preceding some of these events, we'll be able to pick that up. I do think a lot of ⁓ the medical exam, not a hundred percent, a lot in the future, will be digital data, smartwatch, facial recognition, other data. And then I think you will add biochemical data on it and probably microbiome data, but you could do a lot of it at home. And then people would get measured a lot more too. Meaning you would just periodically, we've set up something called microsampling where you do little drops of blood, mail it in. And yeah, one of my companies does this, you get ⁓ measurements on six hundred and fifty metabolites that cover all these tw 20 wellness areas, inflammation, ⁓ oxidative stress, heart health, kidney health, all these things. ⁓ and you could combine that with microbiome, which you could also measure at home, right? And suddenly you've got both biochemical pictures of people and microbial pictures as well as these digital ones. And I think you could deduce a heck of a lot from the this information. And and I think then we can measure people at home much more frequently so we can catch again, track people's health, not wait every two years when they come into the doctor when they're ill. And that just shifts the whole paradigm. We've got to keep people healthy or we're gonna keep operating in this broken healthcare system we're in now. Yeah, I mean this is obviously amazing. We could discuss for hours. ⁓ let's we we only have a few minutes left, so let's touch upon a couple of po points here. So I think so even though wearables are not necessarily very precise, meaning ⁓ they don't they don't actually have clinical level of precision of measuring individual markers. If you have enough longitudinal data points and you establish that baseline, when that baseline changes relative to your own baseline, you can then deduce that something's wrong and you can go get it checked out with more precise markers, right? Yep. So I really like that. For example, blood pressure would be one of them. Maybe blood pressure, you know, smart smart devices are not super accurate, but if if your blood pressure keeps creeping up, then something's wrong and you should go get it checked out. And that's obviously a super important metric. And then I'd like to Go back to ⁓ salute. I would like to By the way, by the way, Momo, I I do have a blood pressure monitor from ⁓ you know from one of these companies which is you know, and I and I take it every every week. And so i it's not every day, but every week I think is it's reasonable. It's reasonable, yeah. And then so Mike, Salud, ⁓ let's just touch upon type two diabetes because that's a obviously a huge topic of of huge importance. So are you saying that there are two subtypes of type two diabetes? If we just focus on type two diabetes, there are two subtypes. One is the ⁓ inability or reduced ability to re to ⁓ to ⁓ produce insulin or release insulin into the bloodstream. And the other one is what's classically known as insulin resistance, where you your cells are actually not responding to insulin. Is that the two or there are others? No, there are more than that, believe it or not. So ⁓ even muscle insul resistance you can break or sorry, insulin resistance you can break in the subtypes. There's muscle insul resistant, which is the major form, but there's hepatic insulin resistance, so your liver. There's also adipose insulin resistance. There it then on top of that, there's a beta cell defect. Right. ⁓ and then on top of that, there's also incredible, these GLPs. ⁓ they're actually natural hormones in the body, and there are people who have defects in that pathway as well. Okay. So you can be defective in any of these areas or combinations thereof. Now it is true that musclens resist them beta cell the most common ones, but these others are out there too. They're not zero. And just in the shape of a curve, we can predict musclin's resistance beta cell, shape of a glucose curve. So that means you can now get your subtype. ⁓ w we we haven't fully released this, but we will soon. You can get your subtype just from a simple at-home test. And we think that's very powerful. Okay. So so when you release these, what are you talking about you have a company that will offer this as a product? Believe it or not, no. ⁓ in all the companies we have, ⁓ this is one that is not doing it. Although I think there's a company in India called IOR that actually I'm part of an advisor on that will incorporate it there. I've been trying to get cut some of the companies here to incorporate it. So in the end, if nobody picks it up, we'll just toss it up there as an a a a free at home test that anybody can do. Okay. And so in fact, we did that for the infectious disease detection. Okay. So in other words, someone would be collecting CGM data and then apply some some some mechanism, some method that you would release publicly. You would just upload it, yep, onto a website if we put it. That's that to be honest, that's the most likely plan that'll emerge. That is amazing. Load it up there and then you'll see what your subtype is. I want to point out that we're very predictive from muscle insurance and a beta cell defect. We're not so predictive for the others yet, meaning we'll probably have to add other information or improve our algorithm. But but those two are the most common ones and your approach to fixing or preventing those is very different. So those are those basically cover most people. It is, yeah. No, we think it's very, very powerful. So so Mike, we would love to have you as a guest on the podcast when you actually provide that website and we can maybe all three of us can wear CGMs prior to the podcast and then we can actually upload our data and and ⁓ and do it actually on the podcast. Okay, ⁓ that's sounds great, Mohan. I have, you know, before we let you go, Mike, I have one last question for you. ⁓ big picture question. ⁓ so if you had a blank check today. And you had zero regulatory red tape. What is the single biggest moonshot experiment that you would like to run on the human population? Well, I can answer that in several ways. The most obvious is I would like to put a smart watch on everybody on the planet. ⁓ because then there'd be some level of health tracking ⁓ for most of the world. Most of the world has a smartphone, believe it or not. So all you have to do is put a watch on pair or a ring, pair it with them, and suddenly you've got some level of health monitoring. And I predict that by itself would lead to an increase in people improving their health. ⁓ Now, you do it it'd be good to incentivize people. So this is why this answer could get a little more convoluted. The biggest problem we have with healthcare today is there's no incentive for keeping people healthy. So I think we should have plans that actually give you points for wearing a smartwatch, ⁓ use points meaning a reduction, maybe your payments are less, ⁓ points for getting your genome sequence, points for getting your microbiome done. Do these things that are useful for keeping you healthy. And that I think is what would change the way we ⁓ you know, medicine is done today. That's amazing. Actually that I agree with you completely that we should ⁓ incentivize people by reducing their insurance premium if they do all these things, just like they do in the you know, in the car industry, right? In the you know, you if you drive safely and if you take a device ⁓ that your your thing that tracks you driving, they reduce their your you know your premium. I mean, I think we should do the same thing in health. I agree. Amazing. Yeah. Amazing. I might get a smartwatch just based on this conversation. Thank you. I hope so. Yeah. You don't need all four. Just one will do the just one. I'll just get one. Dr. Snyder, it's a huge pleasure to have you as a guest. We're looking forward to the next episode when we can discuss these subtypes of type two diabetes and more. Thank you very much. Thank you so much, Mike. Next time. Thanks for having me. Awesome. Bye now. We could continue talking to him for hours because there's so many great t topics and he's got so many results over such a long distinguished career and so many common topics of interest with us that we could just keep going on and on. But we will. ⁓ Part of the episode today is to get questions from the audience. So there was a question from the ⁓ from one of our audience members which said, Are there any microbiome areas that you might extend into in the future, like skin or vagina? So Momo, go for it. Yeah. So ⁓ we we are always looking at what kind of tests can we bring to market to make the biggest impact ⁓ for our customers and for people in general. And ⁓ When it comes to skin microbiome, we actually had a very serious RD effort and we kind of locked in the test. But by the time we did that and we're considering going to market strategy, we actually realized both from the literature and from our own data and from our customer feedback that skin microbiome actually plays a minor role in skin health. It's really the gut microbiome that plays a major, major role in skin health. And so we really ⁓ took that off the table. And so I'm not really sure if or when we would bring a skin microbiome test to the market because it's not really showing ⁓ much relevance and we don't want to just offer another product ⁓ for you know no reason at all. So that's about skin. Now vaginal microbiome is very, very important. That's very well known. But here's the thing ⁓ our ⁓ CEO's daughter Priyanka Jane actually founded a company to focus specifically on vaginal microbiome. And we're friends with them, and I'm one of the earliest advisors of the company. So look up EVI, E V V Y, and EVI has the most advanced gut vaginal microbiome test, both in terms of like the molecular test, but also most importantly the interpretation of the test. And so we have no reason to offer vaginal microbiome tested biome because EV's got it. So look into And I spoke to our Actually, I spoke to her this morning and ⁓ they you know the the studies they're doing, the clinical studies they're doing are actually really great, right? So they're looking at the impact of different types of ⁓ issues with the vaginal microbiome ⁓ related to ⁓ female health ⁓ and other kinds of, you know, procedures that people people may go through and so forth. So yes, they've got solid science and they are ⁓ doing a great job giving ⁓ giving the market a product. They're on the cutting edge of both the science and interpretation, clinical interpretation, which is what women need. They they don't need just data because if they take those data to normal doctors, they're not gonna know what to do with it. It's just such a cutting edge science. So Evi's really doing the translational science piece very well. And ⁓ I'm very proud of them. Okay, so that was that. No, wait. ⁓ there was there was another important point I wanted to highlight is that our metatranscriptomics assay that you built. is applicable to literally any type of sample, right? So that you can type a biological system. It can be deep ocean vents, it can be air filters, it can be tissue biopsies, soil. It doesn't matter. Exactly. So you know whether it's a human sample, whether it's an environmental sample, whether it's an animal sample, whatever it is, if we can get those samples into the lab in a preserved way. then we can do the same metatranscritomic assay. So there's a lot of possibilities in the future because we don't have to build a new assay because it is a very, let's call it a comprehensive assay and it's also generalizable to any type of sample. And that's that's important for people to know. Yeah. And on that topic, I do want to mention that we have fully developed and validated a an environmental test that would include molds. And molds are of of a huge medical concern. And so I think we have the most advanced mold test in the world. And and there are two reasons for that. One is that it's completely unbiased. We're not we're not doing tests that test for specific molds that we're looking for. We're looking for all of them at the same time. And second reason it's the most advanced is because our fungal database of medically relevant fungi is the most advanced in the world because we made a significant investment in that. And so I think the combination of those two would make it very, very useful for a lot of people. ⁓ unfortunately we don't have the bandwidth to go to market with that test. And so if there are entrepreneurs out there who want to white label our test and and market it in a big way, we're only looking for big way, not small way, then go ahead and contact us in any way and ⁓ and let's go. And you know, we've also dabbled into animal microbiome like cats and dogs and horses, but it's just ⁓ we really need to focus on what's the most important at the time. Which is human disease, human chronic disease. Yes. Right. Speaking of which. Speaking of which, we are starting another interesting segment of our podcast. And we will probably repeat this in many episodes. And that's gonna be called in the news, right? What is a major exciting piece of news that's out there for everybody to consume and What is underneath it? Not just talking about the headlines, but what is underneath it and provide a view on what the reality of the situation is, what the science underneath it is, and what the impact on health is. So I'm gonna start with a piece of news that came out in the New York Times. ⁓ I think it was yesterday. this was a major, major study that was run by the pharma company Novo Nordisk. And they had I mean they called it Zeus. That's the name of the name of the I mean speaking of speaking of the Odyssey, I think it comes right back to the Greek mythology here, right? So Zeus, the study, had a hypothesis that said that inflammation is the underlying root cause of C V D. And in particular, they went after the I L6 cytokine. And some potentially some related. Related things, but they did they developed a molecule that would ⁓ suppress IL6 and would suppress other proteins like CRP. And they, you know, their hypothesis was this is going to lead to a an improvement in cardiovascular disease, specifically atherosclerosis. And so they recruited a lot of people, I think 6,000 plus people with the disease. They gave them this. Medication for a period of time and then they measured it just last week, apparently, they published that they did not impact their primary endpoint, which was the disease itself, the cardiovascular disease itself. Even though they did measure the IL-6 and the CRP and all the other inflammatory markers that they were targeting, those markers did reduce, but the disease did not. So, Momo, I'm gonna turn it around to you, the molecular scientists, and ask you: so what is going on here in this inflammation hypothesis? Yeah, I mean, I think that ⁓ traditional drug design goes after one target, right? And that has worked for decades. However, the complexity of human biology is such that when we talk about inflammation, we're not talking about one or two molecules, we're talking about hundreds of molecules. And It's very unlikely that one molecule is going to be such an important factor in a disease that if you knock it down, that it'll basically prevent a disease. Now, it has happened in the past, and so TNF alpha is the first such target. So TNF alpha is another cytokine that's a central player in the immune system. And actually the ⁓ the the most lucrative drug that drug ⁓ type that has been on the market since early two thousands. are these monoclonal antibodies or biologics against TNF alpha. And that has worked fairly well. It works really well in some people. It doesn't work well in others. ⁓ and so Nova Nordisk, who people will probably know, brought us the GLP1 ⁓ receptor agonists. They went after this IL6 target, which very strongly associates with cardiovascular disease. And they thought that it was going to be the next TNF alpha. Unfortunately that didn't That didn't turn out to be the case. And what that tells us is either they didn't dose it properly, meaning they didn't knock it down sufficiently enough to where they can see the results, or much more likely, there are many redundant inflammatory pathways, many others that are contributing to cardiovascular disease risk or cardiovascular disease in general. And that means that knocking down one of them is just not going to have a significant impact on disease. And that I think is Sort of like the core of what we do at VIOM. We at VIOM are not targeting one thing. We're actually looking at hundreds of pathways both in the gut microbiome and oral microbiome and human blood, and then modulating hundreds of those at the same time with, you know, thousands of micronutrients in order to shift the balance towards less inflammatory. And when you shift that whole balance, you're impacting many, many different pathways and not just one molecule. So yeah, I'm not super surprised. feel bad obviously for, you know, on average to bring dru a drug to the market costs $3.2 billion. So they've spent a lot of time and money ⁓ doing this and it failed. So that's unfortunate. Yeah, unfortunate. But ⁓ you know, i i very interesting and important result in the sense that, you know, people cannot kind of reduce everything. You know, there's a reductionist view that you reduce everything to like one thing. That's not likely to work a lot. There's a lot of multifactorial stuff going on and that's kind of what we do. So Momo, what else is in the news? Well, I just want to bring up this paper that I will actually list in the show notes ⁓ that I found fascinating in that the rate of food allergies and sensitivities has been increasing for decades. And these things used to be super rare like 50 years ago and now they're super common. We've normalized the fact that people are allergic to different foods. And ⁓ What is not known is what is the root cause of that. And we've had good evidence that it's the gut microbiome that actually d determines these things. And so I just want to point out two papers that I will list. One paper specifically shows that gut microbiome, and it was mechanistically shown in mice, gut microbiome determines the fate of specific immune cells called T cells in the lining of the gut, where if they if they convert themselves to a specific type of a cell. They release cytokines that tell B cells to switch to making IgEs. And these IgEs are antibodies that basically facilitate allergy, allergy responses. But the other effect of the microbiome can be that these T cells convert to these so-called T helper cells, and they actually recognize food as food and and develop tolerance. And so, really, the very first signal for whether we're going to be allergic or tolerate a food starts with the gut microbiome. So that's really, really nice. And now this second paper that just came out literally yesterday shows mechanistic view into this that actually has to do with bile acids. So bile acids are ⁓ complex molecules that our liver produces and our pancreas releases that solubilize fats in our food. And some of those bile acids make it to the colon where micro microbiome processes them. And basically they're showing that when these bile acids are processed by specific microbial members in the colon. We do not develop allergies. But if they lack there, then they then then if there's a lack of that of that physic you know ⁓ biochemical function, then the person and the mouse develop food allergies. And so this is really exciting to us because we are going to be offering soon a food allergy product and it's gonna be combined with our very deep microbial understanding. And so really for me, the most exciting thing is that Maybe in a year or two or three or five, we're gonna be able to in a very deterministic way modulate the microbiome to prevent allergies. And that's really where we want to be. That would be that would be amazing, Momo. That would be amazing. So okay, so it sounds like ⁓ we have a bio monthly challenge winner. Woohoo. We do. So yeah, go ahead, Guru. Yeah. Okay, let me let me let me say this. So it is at Chris's Brink nine two seven two who made the comment. Remember the challenge was for us for you to make a a really good comment, interesting and relevant to a people. Right? So it's ⁓ so it's he's our question, correct? Our question. So he says Knowing that DNA is static and RNA is dynamic, I'm curious about your thoughts on how frequently the average consumer would need to test their molecular data. Awesome question. Awesome question. And turns out we just published a paper on this topic just a few months ago, and we took a number of customers off Biome, more than 6,000 of them, and we looked at the rate of change of their microbiome and the significance of the change from time zero to month one to month two and so on, all the way to month twelve. We found that approximately around the six-month mark. Is when the microbiome changed significantly, meaning statistically significantly, when you compare each time point to the previous time point and use all the statistical measures, you can determine whether something is statistically significant or not. And around the six-month mark is when it changed significantly. So the way we take take away that that result or finding from the analysis is that yes, your microbiome changed to changes a little bit. based on your actions on any given day or couple of days, week and so forth, but it takes an entire half a year, two quarters for the microbiome to change enough, meaning significantly, to settle into a new steady state, so to speak. So because of that, we recommend that all consumers do a retest of their biome Molecular test every six months. That's our recommendation because we think that if you take our supplements or any of the recommendations that we make seriously and we you actually make the changes that we recommend, it will take you approximately six months to get to that new steady state. Of course, the I mean, I'll put a caveat in here. If you have some dramatic event in your life, like for example, you have a surgery or or you have a an antibiotic. regimen treatment. You know, you or you move to some other place and you c dramatically change your diet or something like that, that could have a slightly bigger impact. We did not actually in that paper we studied one particular interesting thing, which is that after doing a colonoscopy, that your microbiome actually bounces back within a couple of weeks. But if you had something really dramatic, maybe it it'll be a little bit faster. But on average or general, I would say it would be about six months. Yep. Awesome. So yeah, congratulations. And so what we need is we need at Chris Brink nine two seven two. If you can please email us at podcast at viom dot com and ⁓ just show yourself to us and then ⁓ we will be providing you with a free full body intelligence kit for free. So please email us and we'll go from there. So congratulations. Congratulations, Chris Brink. ⁓ you're the lucky, lucky person. Well Lucky and and ⁓ pretty in tune with what's going on with the human biology and RNA versus DNA. So pretty cool. ⁓ so that's all we have for today's episode. Thank you so much for listening. I am Omo, a biochemist. And I'm Guru, a data and AI expert. We're two PhDs on a pod. All right, see you next time. Bye bye next time. Two PhDs on a pod is a Viome Health Science Podcast production, written and hosted by Viome CTO Guru Banavar and Vyome CSO Momo Vuisic. Produced and edited by Lisa Shomo. Podcast Art by Kevin Wu. If you enjoyed today's episode, like and subscribe for new episodes every other week. We'll see you next time.